 SOUTH SAN FRANCISCO, Calif., July 12, 2022 GLOBE NEWSWIRE -- UNITY Biotechnology, Inc. UNITY NASDAQ: UBX, a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that 24-week clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the American Society of Retina Specialists ASRS 40th Annual Scientific Meeting 2022, being held July 13-16, 2022. Details of the presentations are as follows: 